TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04488159
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT04488159
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion
Study: NCT04488159
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion
Study: NCT05889442
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
Study: NCT05125718
Drug: 0.85% synthetic antimicrobial peptide TAPS-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
Study: NCT05125718
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: commercially available normal saline Sodium Chloride irrigation solution
Study: NCT06505941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-cell-containing placebo
Study: NCT05688215
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05688215
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05688215
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05465798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
Study: NCT06439433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a week for 6 weeks
Study: NCT03418649
Drug: Eplerenone 50 Mg Tab
Normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg PO per day for 10 days
Study: NCT03418649
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO once daily for 10 days
Study: NCT05005845
Drug: NFX-179 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFX-179 topical gel is the active investigational product being studied
Study: NCT05005845
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFX-179 vehicle gel is the placebo comparator for this study
Study: NCT05247970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule to S-309309 administered orally
Study: NCT06443710
Drug: Technetium [99mTc]-H7ND injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
Study: NCT06174688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injections
Study: NCT04992065
Drug: NNC0385-0434 A 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study: NCT04992065
Drug: NNC0385-0434 A 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study: NCT04992065
Drug: NNC0385-0434 A 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study: NCT05201430
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
Study: NCT05201430
Drug: CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
Study: NCT05136274
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
Study: NCT06241638
Drug: Vitamin B12 0.5 MG/ACTUAT
Normalized name: vitamin B12 0.5 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study: NCT05818917
Drug: FHND5071
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data.
Study: NCT05723432
Drug: KD6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KD6001 will be administered intravenously.
Study: NCT04809818
Drug: LT3001 drug product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of LT3001 drug product administered by intravenous infusion
Study: NCT04809818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Placebo administered by intravenous infusion
Study: NCT05639153
Drug: DR30303
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
Study: NCT06193408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT04720716
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 IV d1, Q6W
Study: NCT06055257
Drug: modified PENTOCLO (mPENTOCLO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added.
Study: NCT06281665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive similar appearing placebo daily for 6 months.
Study: NCT05824923
Drug: Guideline-directed medical therapy (GDMT) for heart failure
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion.
Study: NCT04681833
Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Repeat Dose
Study: NCT04681833
Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
Normalized name: respiratory syncytial virus vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Repeat Dose/High Repeat Multiple Dose
Study: NCT04681833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid diluent/Lyophilised Powder
Study: NCT05569057
Drug: SIM1811-03
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
Study: NCT04877275
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2 intravenously on day 1 , QW
Study: NCT04930549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo tablets once a day during 12 weeks
Study: NCT04877275
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide：300mg/m2, d1 QW，
Study: NCT05926349
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per the label of the chosen usual care product(s) and/or usual care standards.
Study: NCT05678205
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT05634746
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally disintegrating tablet.~Other Names:~PBO
Study: NCT05082051
Drug: Part B
Normalized name: Hem-Care Premium 7-Part Blend Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each.
Study: NCT06490653
Drug: Blood Stopper (Ankaferd)
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
Study: NCT06606093
Drug: DWP16001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT06606093
Drug: DWP16001 0.3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT06608056
Drug: Pain management after surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
Study: NCT06607016
Drug: KJ103 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
Study: NCT06607016
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hence treatment prevents formation of new anti-GBM antibodies.
Study: NCT06607016
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids inhibit the inflammation process.
Study: NCT06605300
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to receive intranasal administration of placebo.
Study: NCT06606821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
Study: NCT06606015
Drug: I.V Paracetamol.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological thereby for hsPDA closure in the preterm neonates.
Study: NCT04854044
Drug: Akt/ERK Inhibitor ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT06239441
Drug: IL5/IL5R Antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with IL5/IL5R antagonists for one year
Study: NCT06411912
Drug: NIDO-361
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 100mg of NIDO-361 for oral administration.
Study: NCT06411912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets
Study: NCT04309877
Drug: Theophylline ER
Normalized name: Theophylline ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of theophylline ER
Study: NCT06379958
Drug: leramistat 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06379958
Drug: Phenytoin 100 Mg Oral Capsule
Normalized name: phenytoin 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06379958
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04703608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-identical placebo
Study: NCT05730543
Drug: Volbella or Juvederm Ultra XC filler
Normalized name: Hongo Killer Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronic acid filler
Study: NCT06238843
Drug: IBI343
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles
Study: NCT06305715
Drug: Targeted TKI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
Study: NCT05142254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
Study: NCT05908071
Drug: SHEN26 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally after meals.
Study: NCT05908071
Drug: SHEN26 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally after meals.
Study: NCT06017921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
Study: NCT04705597
Drug: BGE-175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT06040203
Drug: Placebo (saline solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
Study: NCT05308472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, once a day for 120 days
Study: NCT05641428
Drug: ARI-0001
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Study: NCT04694755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
Study: NCT04694755
Drug: Traditional Chinese medicine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianjiang brand formula granules, in line with GMP standards
Study: NCT05728788
Drug: Antitumor drugs
Normalized name: SHIITAKE MUSHROOM 15 g in 100 g ORAL LIQUID [SALANA 153 (Blood circulation, Cytothesis, Thrombolysis, Immunity boost, An antitumor, Antiinflammatory, Regulatory action, Inhibitory action, Exocytosis)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
Study: NCT06605105
Drug: CYB003
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYB003 is a synthetic psilocybin analog
Study: NCT06607887
Drug: IV antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
Study: NCT06607887
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
Study: NCT05440006
Drug: Fuzuloparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib Capsules; 150mg; single dose per cycle.
Study: NCT04788797
Drug: Prolyl Endopeptidase
Normalized name: Prolyl endopeptidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules three times a day.
Study: NCT05417269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only.
Study: NCT04384601
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy will be administered according to description in two arms.
Study: NCT00027365
Drug: AS02A Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06343870
Drug: testosterone pellet (100 mg)
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
Study: NCT06343870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pellet of cholesterol (placebo)
Study: NCT06279104
Drug: physician's choice of chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
Study: NCT05019742
Drug: SPH3127
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 - selective renin inhibitor
Study: NCT05019742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04713904
Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT04713904
Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evafem 20 (Trademark)
Study: NCT06344052
Drug: SP-002
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
Study: NCT05683574
Drug: FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study: NCT05683574
Drug: etoricoxib 90 mg (Arcoxia®) +FDC placebo
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study: NCT05683574
Drug: cyclobenzaprine hydrochloride + etoricoxib placebo
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study: NCT06035393
Drug: HRG2005 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: dose 1; dose 2; dose 3
Study: NCT06035393
Drug: Placebo to match HRG2005 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 2
Study: NCT04863248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
Study: NCT05108025
Drug: Topical Powder
Normalized name: Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Powder mixed with diluent
Study: NCT05108025
Drug: Placebo Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Powder mixed with diluent
Study: NCT06605963
Drug: PPV-06
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Study: NCT05447702
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion.
Study: NCT06605963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Study: NCT00377546
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00377546
Drug: Ketorolac LS, Bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05948228
Drug: giomer based bioactive gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of bioactive gel to prevent white spot lesions in orthodontic patients